SCHEMBL13227643

SCHEMBL13227643

CCC(C)(C)n1ccc2c(Cl)cccc21

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.45
NR3C2 P08235 8/20 0.40
PGR P06401 3/20 0.37
NR3C1 P04150 2/20 0.37
HTR6 P50406 1/20 0.35
CYP1A2 P05177 3/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2A6 P11509 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
CCR2 P41597 1/20 0.33
HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13209355 0.82 NOTUM (0.50) NOTUMNR3C2PGRNR3C1HTR6
SCHEMBL26627923 0.80 NR3C2 (0.34) NR3C2PGRNR3C1CYP3A4HTT
SCHEMBL31560801 0.75 NOTUM (0.55) NOTUMNR3C2PGRNR3C1HTR6
SCHEMBL31560833 0.75 NOTUM (0.48) NOTUMNR3C2PGRCYP1A2CYP3A4
SCHEMBL12386866 0.72 CDK4 (0.44) NOTUMHTR6SLC6A2SLC6A4
SCHEMBL13311382 0.72 NOTUM (0.50) NOTUMHTR6CYP1A2CYP2A6SLC6A2
SCHEMBL4313476 0.70 NOTUM (0.45) NOTUMNR3C2CYP1A2CYP2A6SLC6A2
SCHEMBL1092615 0.69 HSD11B1 (0.57) NOTUMNR3C2CYP1A2CYP2A6HSD11B1
SCHEMBL24254236 0.68 TLR7 (0.35)
SCHEMBL12383495 0.67 NOTUM (0.45) NOTUMNR3C2CYP1A2CYP2A6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329718-B2 N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2012-12-11 US disclosed
US-20100197716-A1 N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197716-A1 N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS P2RY1, P2RY11, P2RY13 NOTUM 4169/4885NR3C2 1060/4885PGR 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.